I think this statement is the most significant.
Post# of 72436
"In addition, the detection of p21 expression at 24 hours after Kevetrin administration, coupled with the known short half-life of Kevetrin in plasma, is consistent with an intracellular site of action of Kevetrin."
Leo is telling us that the MOA of K in humans is exactly the same as in mice. And we know what happens to the xenografted tumors in mice. In case you don't get the hint, Leo is saying it again.
"It is exciting to see our early clinical work in the lab translating to the bedside."
Yet some over there are saying p53 activation doesn't mean sh*t. That's just pathetic.
Quote:
Statistics back up the anecdotal evidence of some stabilization in some patients in the Phase 1. That level of measurable activity with a biomarker for the p53 gene is impressive since they're measuring what happens with only one dose. Given the short half-life of Kevetrin, the 3 dose/week regimen they're planning for the ovarian cancer trial should be even more effective. Very encouraging news for $CTIX, hope people understand what great news this is.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
![Dont-give-up.jpg](https://styleshack.com/wp-content/uploads/2014/07/Dont-give-up.jpg)